{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T02:22:41Z","timestamp":1792462961918,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,19]],"date-time":"2021-11-19T00:00:00Z","timestamp":1637280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018262","name":"Intercept Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018262","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000774","name":"Newcastle University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016915","name":"Inventiva Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016915","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004321","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004321","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004628","name":"MedImmune","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004628","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.cgh.2021.07.020","type":"journal-article","created":{"date-parts":[[2021,7,15]],"date-time":"2021-07-15T12:41:36Z","timestamp":1626352896000},"page":"2050-2058.e12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":85,"title":["Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9313-577X","authenticated-orcid":false,"given":"Zobair M.","family":"Younossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Stepanova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatema","family":"Nader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin M.","family":"Anstee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Ratziu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rn M.","family":"Schattenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Sidney","family":"Barritt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazen","family":"Noureddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Bonacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gail","family":"Cawkwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Rinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2021.07.020_bib1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1055\/s-0035-1562942","article-title":"Diagnosis and assessment of NAFLD: definitions and histopathological classification","volume":"35","author":"Burt","year":"2015","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.cgh.2021.07.020_bib2","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.020_bib3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fmed.2019.00061","article-title":"The patient perspectives on future therapeutic options in NASH and patient needs","volume":"6","author":"Cook","year":"2019","journal-title":"Front Med"},{"key":"10.1016\/j.cgh.2021.07.020_bib4","doi-asserted-by":"crossref","first-page":"S149","DOI":"10.1016\/j.jval.2018.09.890","article-title":"Patients with non-alcoholic steatohepatitis (NASH) have worse Health Related Quality of Life (HRQOL) than matched controls: results from the 2016 EU5 National Health and Wellness Survey (NHWS). Poster PGI48","volume":"21","author":"Balp","year":"2018","journal-title":"Value Health"},{"key":"10.1016\/j.cgh.2021.07.020_bib5","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhepr.2019.05.009","article-title":"The burden of non-alcoholic steatohepatitis (NASH) among patients from Europe: a real-world patient reported outcomes study","volume":"1","author":"Balp","year":"2019","journal-title":"JHEP Rep"},{"key":"10.1016\/j.cgh.2021.07.020_bib6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s41687-018-0052-7","article-title":"Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review","volume":"2","author":"Kennedy-Martin","year":"2018","journal-title":"J\u00a0Patient Rep Outcomes"},{"key":"10.1016\/j.cgh.2021.07.020_bib7","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.cgh.2019.02.024","article-title":"Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.07.020_bib8","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.cgh.2018.12.016","article-title":"Health-related quality of life in nonalcoholic fatty liver disease associates with hepatic inflammation","volume":"17","author":"Huber","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.07.020_bib9","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1111\/liv.13706","article-title":"Improvement of hepatic fibrosis and patient-reported outcomes in non-alcoholic steatohepatitis treated with selonsertib","volume":"38","author":"Younossi","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.cgh.2021.07.020_bib10","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.cgh.2019.01.001","article-title":"Validation of chronic liver disease questionnaire for nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.07.020_bib11","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1016\/S0140-6736(19)33041-7","article-title":"Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial","volume":"394","author":"Younossi","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.cgh.2021.07.020_bib12","unstructured":"National Institute of Cancer. Common terminology criteria for adverse events (CTCAE). National Institutes of Health Publication 2010;2009:1\u201371. Available from: http:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/ctcaev3.pdf. Accessed September 1, 2021."},{"key":"10.1016\/j.cgh.2021.07.020_bib13","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"key":"10.1016\/j.cgh.2021.07.020_bib14","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets","volume":"15","author":"Van Hout","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.cgh.2021.07.020_bib15","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s10198-014-0638-9","article-title":"EQ-5D in skin conditions: an assessment of validity and responsiveness","volume":"16","author":"Yang","year":"2015","journal-title":"Eur J Heal Econ"},{"key":"10.1016\/j.cgh.2021.07.020_bib16","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/gut.2007.139303","article-title":"Fatigue in non-alcoholic fatty liver disease (NAFLD) is significant and associates with inactivity and excessive daytime sleepiness but not with liver disease severity or insulin resistance","volume":"57","author":"Newton","year":"2008","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.07.020_bib17","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1002\/hep.27161","article-title":"Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens","volume":"59","author":"Younossi","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.020_bib18","doi-asserted-by":"crossref","first-page":"S192","DOI":"10.1513\/AnnalsATS.201802-144AW","article-title":"Idiopathic pulmonary fibrosis is a genetic disease involving mucus and the peripheral airways","volume":"15","author":"Schwartz","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.cgh.2021.07.020_bib19","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/ejhf.696","article-title":"Myocardial fibrosis: biomedical research from bench to bedside","volume":"19","author":"Gy\u00f6ngy\u00f6si","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.cgh.2021.07.020_bib20","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/j.jhep.2014.06.034","article-title":"Health related quality of life in people with advanced chronic liver disease","volume":"61","author":"Orr","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cgh.2021.07.020_bib21","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1053\/j.gastro.2015.05.044","article-title":"Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease","volume":"149","author":"Du Plessis","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.07.020_bib22","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.jpainsymman.2017.05.003","article-title":"Association of inflammatory cytokines with the symptom cluster of pain, fatigue, depression, and sleep disturbance in Chinese patients with cancer","volume":"54","author":"Ji","year":"2017","journal-title":"J\u00a0Pain Symptom Manage"},{"key":"10.1016\/j.cgh.2021.07.020_bib23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2147\/CEG.S123942","article-title":"Fatigue in patients with inflammatory bowel disease is associated with distinct differences in immune parameters","volume":"10","author":"Vogelaar","year":"2017","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.cgh.2021.07.020_bib24","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1365-2222.1992.tb00161.x","article-title":"A\u00a0research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid","volume":"22","author":"Gibson","year":"1992","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.cgh.2021.07.020_bib25","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1002\/hep.30946","article-title":"The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis due to NASH","volume":"70","author":"Loomba","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.020_bib26","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1111\/bjd.16117","article-title":"British Association of Dermatologists\u2019 guidelines for the investigation and management of generalized pruritus in adults without an underlying dermatosis, 2018","volume":"178","author":"Millington","year":"2018","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cgh.2021.07.020_bib27","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1038\/s41591-019-0660-7","article-title":"Three-dimensional spatially resolved geometrical and functional models of human liver tissue reveal new aspects of NAFLD progression","volume":"25","author":"Segovia-Miranda","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.cgh.2021.07.020_bib28","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1007\/s10620-015-3776-8","article-title":"Altered bile acid metabolome in patients with nonalcoholic steatohepatitis","volume":"60","author":"Ferslew","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cgh.2021.07.020_bib29","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.cgh.2021.07.020_bib30","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1056\/NEJMoa1509840","article-title":"A\u00a0placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cgh.2021.07.020_bib31","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1111\/bjd.17933","article-title":"Pruritus secondary to primary biliary cholangitis: a review of the pathophysiology and management with phototherapy","volume":"181","author":"Hussain","year":"2019","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.cgh.2021.07.020_bib32","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1016\/j.cgh.2019.03.028","article-title":"Alterations in skin microbiomes of patients with cirrhosis","volume":"17","author":"Bajaj","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.07.020_bib33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12882-017-0475-z","article-title":"Transformation of 5-D itch scale and numerical rating scale in chronic hemodialysis patients","volume":"18","author":"Lai","year":"2017","journal-title":"BMC Nephrol"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521007515?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1542356521007515?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:37:55Z","timestamp":1761543475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1542356521007515"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":33,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1542356521007515"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2021.07.020","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2021.07.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}